Aytu BioPharma (AYTU) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed NextCure (NXTC) over the past year, gaining 32.3% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -93.2% for AYTU. NextCure is the larger company by market cap ($29.5 million vs $28.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | NXTC |
|---|---|---|
| Share price | $2.66 | $6.45 |
| Market cap | $28.91M | $29.53M |
| 1-day change | 0.00% | -4.87% |
| YTD return | +2.31% | -54.55% |
| 1-year return | +32.34% | -38.63% |
| 5-year return | -93.21% | -91.07% |
| Forward P/E | 17.16 | — |
| EPS (TTM) | $-1.78 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $57.57M | — |
| Revenue growth (YoY) | -13.27% | — |
| Net income (latest FY) | $-14.25M | $-55.84M |
| Gross margin | 63.95% | — |
| Operating margin | -14.44% | — |
| Net margin | -24.76% | — |
| 52-week high | $3.07 | $15.74 |
| 52-week low | $1.75 | $1.55 |
| Distance from 52-week high | -13.36% | -59.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +263.53% | +210.08% |
| Average volume | 141.18K | 79.46K |
| Shares outstanding | 10.87M | 4.58M |
| Employees | 75 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed NXTC by 71.0 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
AYTU vs NXTC FAQ
Which is bigger, Aytu BioPharma or NextCure?
NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $28.91M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, AYTU or NXTC?
AYTU returned +32.34% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.